The Pharma Letter M&A roundup - April 2023

9 May 2023

A bumper month of M&A activity in March gave way to one with just three acquisitions in April—albeit two of those were multi-billion dollar deals.

There was nothing on the scale of Pfizer's (NYSE: PFE) $43 billion buy of Seagen, which was announced in March, but another US pharma giant did spend big, in the shape of Merck & Co (NYSE: MRK).

As well as Merck's $10.8 billion acquisition of Prometheus Biosciences, UK pharma major GSK (LSE: GSK) announced a significant deal of its own, buying up Bellus Health for some $2 billion.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK